THE FIGHT INHERITED RETINAL BLINDNESS! PROJECT: A NEW TREATMENT OUTCOME AND NATURAL HISTORY REGISTRY FOR INHERITED RETINAL DISEASE.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-10-10 DOI:10.1097/IAE.0000000000004296
Matthew P Simunovic, Anthony T Moore, John Grigg, Panagiotis Sergouniotis, Omar A Mahroo, Andrea Vincent, Mandeep Singh, M Dominik Fischer, Thomas Edwards, Heather Mack, Michael Hogden, Fred K Chen, Alex Hewitt, Lauren Ayton, Bart Leroy, Robyn Jamieson, Mark C Gillies, Daniel Barthelmes
{"title":"THE FIGHT INHERITED RETINAL BLINDNESS! PROJECT: A NEW TREATMENT OUTCOME AND NATURAL HISTORY REGISTRY FOR INHERITED RETINAL DISEASE.","authors":"Matthew P Simunovic, Anthony T Moore, John Grigg, Panagiotis Sergouniotis, Omar A Mahroo, Andrea Vincent, Mandeep Singh, M Dominik Fischer, Thomas Edwards, Heather Mack, Michael Hogden, Fred K Chen, Alex Hewitt, Lauren Ayton, Bart Leroy, Robyn Jamieson, Mark C Gillies, Daniel Barthelmes","doi":"10.1097/IAE.0000000000004296","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To design and build a new disease registry to track the natural history and outcomes of approved gene therapy in patients with inherited retinal diseases (IRDs).</p><p><strong>Methods: </strong>A core committee of 6 members was convened to oversee the construction of the FIRB! module. A further 11 experts formed a steering committee, which discussed disease classification and variables to form minimum datasets via a consensus approach.</p><p><strong>Results: </strong>The web-based FIRB! registry records baseline demographic, clinical and genetic data together with follow-up data. The Human Phenotype Ontology and Monarch Disease Ontology nomenclature were incorporated within the FIRB! architecture to standardise nomenclature. The registry software assigns individual diagnoses to one of 7 broad phenotypic groups, with minimum datasets dependent upon the broad phenotypic group. Additionally, minimum datasets were agreed upon for patients undergoing approved gene therapy with voretigene neparvovec (Luxturna). New patient entries can be completed in 5 minutes, and follow-up data can be entered in 2 minutes.</p><p><strong>Conclusions: </strong>Fight Inherited Retinal Blindness! (FIRB!) is an organized, web-based system that uses observational study methods to collect uniform data from IRD patients to track natural history and (uniquely) treatment outcomes. It is free to Users, who have control over their data.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IAE.0000000000004296","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To design and build a new disease registry to track the natural history and outcomes of approved gene therapy in patients with inherited retinal diseases (IRDs).

Methods: A core committee of 6 members was convened to oversee the construction of the FIRB! module. A further 11 experts formed a steering committee, which discussed disease classification and variables to form minimum datasets via a consensus approach.

Results: The web-based FIRB! registry records baseline demographic, clinical and genetic data together with follow-up data. The Human Phenotype Ontology and Monarch Disease Ontology nomenclature were incorporated within the FIRB! architecture to standardise nomenclature. The registry software assigns individual diagnoses to one of 7 broad phenotypic groups, with minimum datasets dependent upon the broad phenotypic group. Additionally, minimum datasets were agreed upon for patients undergoing approved gene therapy with voretigene neparvovec (Luxturna). New patient entries can be completed in 5 minutes, and follow-up data can be entered in 2 minutes.

Conclusions: Fight Inherited Retinal Blindness! (FIRB!) is an organized, web-based system that uses observational study methods to collect uniform data from IRD patients to track natural history and (uniquely) treatment outcomes. It is free to Users, who have control over their data.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
防治遗传性视网膜盲症!项目:新的遗传性视网膜疾病治疗结果和自然史登记。
目的:设计并建立一个新的疾病登记系统,以跟踪遗传性视网膜疾病(IRD)患者的自然病史和已获批准的基因疗法的疗效:方法:召集了一个由 6 名成员组成的核心委员会,负责监督 FIRB!另外 11 名专家组成了一个指导委员会,讨论疾病分类和变量,通过协商一致的方法形成最小数据集:基于网络的 FIRB! 注册表记录了基线人口统计、临床和遗传数据以及随访数据。人类表型本体(Human Phenotype Ontology)和君主疾病本体(Monarch Disease Ontology)术语被纳入 FIRB!架构,以实现术语标准化。登记软件将个人诊断归入 7 大表型组之一,最低数据集取决于大表型组。此外,还商定了使用 voretigene neparvovec(Luxturna)进行基因治疗的患者的最低数据集。新患者输入可在 5 分钟内完成,随访数据可在 2 分钟内输入:结论:抗击遗传性视网膜盲症!(FIRB!) 是一个有组织的网络系统,它采用观察研究方法收集 IRD 患者的统一数据,以跟踪自然病史和(独特的)治疗结果。该系统对用户免费,用户可以控制自己的数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
期刊最新文献
A Systematic Review of Sleep Disturbance in Idiopathic Intracranial Hypertension. Advancing Patient Education in Idiopathic Intracranial Hypertension: The Promise of Large Language Models. Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments. Approach to Managing the Initial Presentation of Multiple Sclerosis: A Worldwide Practice Survey. Association Between LACE+ Index Risk Category and 90-Day Mortality After Stroke.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1